2024/03/28 16:32:25 | |
---|---|
Price | |
9.826 EUR | |
Difference | 4.97% (0.47) |
ISIN | CA0717341071 |
Symbol | BHC |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 3,591 EUR |
Benchmark | S&P/TSX 60 INDEX |
Bid (Bid size) | - (0) |
Ask (Ask size) | - (0) |
Open | 9.599 EUR |
High | 9.826 EUR |
Low | 9.599 EUR |
Close (prev. day) | 9.361 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 6 |
Last size | 0 |
Related Futures | 15 |
Related Options | - |
Date | Headline | Download | |
2024/03/13 | Global Equity Ratings | ||
2024/02/22 | Global Equity Ratings | ||
2024/02/14 | Global Equity Ratings | ||
2024/01/23 | Global Equity Ratings | ||
2023/12/21 | Global Equity Ratings |
2024/03/28 16:32:25 | |
---|---|
Price | |
9.826 EUR | |
Difference | 4.97% (0.47) |
ISIN | CA0717341071 |
Symbol | BHC |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 3,591 EUR |
Benchmark | S&P/TSX 60 INDEX |
Bid (Bid size) | - (0) |
Ask (Ask size) | - (0) |
Open | 9.599 EUR |
High | 9.826 EUR |
Low | 9.599 EUR |
Close (prev. day) | 9.361 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 6 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | +26.72% | +42.94% | -62.84% |
Perf (abs.) | +2.07 | +2.95 | -16.61 |
Beta | 1.66 | 1.28 | 1.80 |
Volatility | 39.01 | 55.54 | 69.65 |
Ø price 5 days | Ø volume 5 days (pcs.) | 9.141 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 8.506 EUR (82) |
Ø price 100 days | Ø volume 100 days (pcs.) | 7.455 EUR (67) |
Ø price 250 days | Ø volume 250 days (pcs.) | 7.326 EUR (58) |
YTD High | date | 9.826 EUR (2024/03/28) |
YTD Low | date | 7.017 EUR (2024/01/03) |
52 Weeks High | date | 9.826 EUR (2024/03/28) |
52 Weeks Low | date | 5.152 EUR (2023/05/12) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/03/28 | 22:26 | 9.83 EUR | 0.08 | 12 |
Toronto Stock Exchange | 2024/03/28 | 21:00 | 14.35 CAD | 8.51 | 3,980 |
Stuttgart | 2024/03/28 | 16:32 | 9.826 EUR | 0.00 | 6 |
SIX Swiss Exchange | 2019/06/28 | 17:35 | 24.11 CHF | 0.00 | 1 |
NYSE | 2024/03/28 | 21:00 | 10.61 USD | 40.60 | 22,550 |
Munich | 2024/03/28 | 08:05 | 9.60 EUR | 0.00 | 1 |
Frankfurt | 2024/03/28 | 16:51 | 9.817 EUR | 0.00 | 2 |
Duesseldorf | 2024/03/28 | 08:10 | 9.591 EUR | 0.00 | 3 |
Berlin | 2024/03/28 | 08:05 | 9.60 EUR | 0.00 | 2 |
BAUSCH HEALTH COS. INC. |
- - |
2150 St. Elzéar Boulevard West - H7L 4A8 Laval |
Telefon: +1-514-744-6792 |
Fax: + |
E-mail: - |
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada. |
Joseph C. Papa | Chairman of Managing Board |
Louis Yu | Member of Executive Committee |
Tage Ramakrishna | Member of Executive Committee |
Barbara Purcell | Member of Executive Committee |
Christina Ackermann | Member of Executive Committee |
Dennis Asharin | Member of Executive Committee |
Jeff Hartness | Member of Executive Committee |
Joseph Gordon | Member of Executive Committee |
Kelly Webber | Member of Executive Committee |
Paul S. Herendeen | Member of Executive Committee |
Robert Spurr | Member of Executive Committee |
Sam Eldessouky | Member of Executive Committee |
Scott Hirsch | Member of Executive Committee |
Thomas Appio | Member of Executive Committee |
John Paulson | Chairman of Supervisory Board |
Amy Wechsler | Member of Supervisory Board |
Richard Mulligan | Member of Supervisory Board |
Brett Icahn | Member of Supervisory Board |
Robert Power | Member of Supervisory Board |
Russel Robertson | Member of Supervisory Board |
Sarah Kavanagh | Member of Supervisory Board |
Steven Miller | Member of Supervisory Board |
Thomas Ross | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer